The development of PD-1/PD-L1 inhibitor-induced hyponatremia may involve multiple mechanisms, including the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (15), immune-related endocrine disorders, and factors associated with significant fluid loss resulting from immune-related adverse events (irAEs) (10, 16). Here, CD274 is linked to inappropriate ADH syndrome.